Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

ASX:KGN
ASX:KGNMultiline Retail

ASX Penny Stocks To Watch In April 2026

As the Australian market looks to rebound with a projected 0.2% rise after the Easter long weekend, investors are keeping an eye on global developments such as potential U.S.-Iran ceasefire talks and their impact on market sentiment. In this context, penny stocks—though an older term—remain relevant for those interested in smaller or newer companies that may offer both affordability and growth potential. By focusing on stocks with strong financial foundations, investors can uncover...
NasdaqGS:AMLX
NasdaqGS:AMLXPharmaceuticals

A Look At Amylyx Pharmaceuticals (AMLX) Valuation As Avexitide Hits A Key Phase 3 LUCIDITY Milestone

Amylyx Pharmaceuticals (AMLX) shares are in focus after the company reported that the final participant has been randomized and dosed in LUCIDITY, its pivotal Phase 3 trial of avexitide for post-bariatric hypoglycemia. See our latest analysis for Amylyx Pharmaceuticals. The latest trial milestone arrives as momentum in Amylyx Pharmaceuticals' share price has been building, with a 7 day share price return of 23.98% and a 90 day share price return of 39.02%, set against a very large 1 year...
NYSE:MMS
NYSE:MMSProfessional Services

Assessing Maximus (MMS) Valuation After Recent Share Price Weakness And Undervaluation Debate

Maximus stock overview Maximus (MMS) has drawn investor attention after a period of weaker share performance, with the stock showing negative returns over the past month and past 3 months. This has prompted closer scrutiny of its current valuation and fundamentals. See our latest analysis for Maximus. At a share price of $63.72, Maximus has seen a 30 day share price return of 18.32% and a 90 day share price return decline of 28.50%, while the 1 year total shareholder return sits at a decline...
TSE:8850
TSE:8850Real Estate

Is Starts (TSE:8850) Elevating Legal Oversight To Reframe Its Governance-Driven Investment Story?

In April 2026, Starts Corporation Inc. appointed its legal affairs chief, Takashi Kubota, as an executive officer, following a board meeting held on 2 April 2026 to consider this leadership change. This promotion highlights an increased emphasis on governance, compliance, and legal risk management, which can be especially important for real estate and service companies. Next, we will explore how Kubota’s expanded role in legal oversight could influence Starts Corporation’s investment...
TSX:GMIN
TSX:GMINMetals and Mining

G Mining Ventures (TSX:GMIN) Is Up 15.5% After Surging 2025 Earnings – Has The Bull Case Changed?

G Mining Ventures Corp. has released its full-year 2025 results, reporting sales of US$580.67 million and net income of US$287.86 million, with basic earnings per share from continuing operations of US$1.27. These results show very large year-on-year increases in both revenue and profitability, indicating a major shift in the company’s operating scale and earnings power. We’ll now explore how this sharp step-up in annual sales and net income may reshape G Mining Ventures’ broader investment...
NasdaqGS:AGYS
NasdaqGS:AGYSSoftware

A Look At Agilysys (AGYS) Valuation After Recent Share Price Volatility

Context for Agilysys (AGYS) investors Agilysys (AGYS) has drawn fresh attention after recent share price swings, with the stock showing mixed near term performance and a sharper decline over the past 3 months from a last close of $71.49. See our latest analysis for Agilysys. The recent pullback, including a 39% 3 month share price return decline and 38% year to date share price return decline from $71.49, contrasts with a 1 year total shareholder return of 6.4%, suggesting fading short term...
NYSE:MCO
NYSE:MCOCapital Markets

Assessing Moody’s (MCO) Valuation After Earnings Beat Guidance Raise And Dividend Increase

Moody's (MCO) is back in focus after quarterly earnings topped analyst expectations, with contributions from both its ratings and analytics divisions, along with higher full year earnings guidance and an increased quarterly dividend. See our latest analysis for Moody's. Despite a softer 30 day share price return of 5.91% and a 90 day share price return of 16.66%, Moody's 1 year total shareholder return of 12.47% and 3 year total shareholder return of 53.95% point to momentum that has built...
NYSE:NE
NYSE:NEEnergy Services

What Noble (NE)'s Fully Automated Offshore Guyana Well Means For Shareholders

Noble recently participated in a project with Halliburton, ExxonMobil and the Wells Alliance Guyana team that achieved the first fully automated geological well placement with complete rig automation in offshore Guyana, integrating automated subsurface interpretation, well placement and real-time hydraulics. This milestone in Noble’s offshore operations highlights its role in advancing drilling automation, potentially reinforcing its positioning as a high-tech contractor in complex deepwater...
NYSE:CLX
NYSE:CLXHousehold Products

A Look At Clorox (CLX) Valuation After Softer Earnings And Cautious Growth Outlook

Fresh analyst commentary and Clorox (CLX) management remarks have pushed the stock back into focus as investors weigh cost inflation, trade down risks, currency headwinds, and a softer outlook for category growth. See our latest analysis for Clorox. At a share price of $104.89, Clorox has seen a 3.71% 1 day share price return and a 2.41% 7 day share price return. However, its 1 year total shareholder return of 21.39% and 5 year total shareholder return of 35.24% highlight fading longer term...
NYSE:EPAM
NYSE:EPAMIT

Is EPAM Systems (EPAM) Share Price Misaligned With Its Cash Flow Outlook?

If you are looking at EPAM Systems and wondering whether the current share price reflects its true worth, the valuation picture is more nuanced than a quick glance at the chart suggests. The stock last closed at US$137.02, with a 0.6% move over the past week, a 6.1% decline over 30 days, and returns of 31.6% decline year to date and 5.5% decline over the past year, following even steeper 3-year and 5-year declines of 52.9% and 67.7% respectively. These moves have kept EPAM on the radar for...